PNC-27

PNC-27 – Benefits & Side Effects

PNC-27 – Protocol

PNC-27 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

PNC-27 – Identification

Common Names: PNC-27, Anticancer peptide PNC-27, Membrane-active peptide PNC-27, HDM-2-binding peptide

CAS Number: 1159861-00-3 (primary)

Molecular Formula: C₁₈₈H₂₉₃N₅₃O₄₄S

Molecular Weight: 4031.7-4031.73 g/mol (Da)

Origin & Type Classification:

• Source: Synthetic; engineered chimeric peptide combining p53 HDM-2-binding domain with cell-penetrating sequence

• Biosynthesis: Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS)

• Functional Class: Anticancer peptide; membrane-active peptide; HDM-2-targeting agent; tumor cell necrosis inducer

Additional Information:

• Amino Acid Sequence: H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH (32 amino acids)

• Sequence Composition: p53(12-26) HDM-2-binding domain (Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu) + penetratin/cell-penetrating peptide (Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly)

• Sequence Length: 32 amino acids (32-mer peptide)

• Structural Type: Linear peptide with alpha-helix-loop-alpha-helix three-dimensional architecture when in aqueous solution; adopts "U-shaped helix-coil-helix" structure in membrane-mimetic environments

• Conformational Properties: Strongly amphipathic with alternating hydrophobic and hydrophilic (charged) residues enabling both HDM-2 binding and membrane interaction

• HDM-2 Binding Specificity: p53(12-26) domain directly superimposable on p53-HDM2 crystal structure (PDB 1YCR); maintains HDM-2-binding conformation in solution

• Membrane Interaction Domain: Penetratin sequence (Gln-Phe-Trp-Lys-Val-Gln-Arg-Gly) enables cell and nuclear membrane penetration through electrostatic and hydrophobic interactions

• Salt Form: Available as free peptide, trifluoroacetate (TFA)-free powder, or acetate salt; white lyophilized powder

• Purity: >95-98% verified via HPLC and mass spectrometry

• Fluorophore-Labeled Variants: Available with N-terminal fluorophore (FITC, green fluorescent protein) and C-terminal fluorophore (TAMRA, red fluorescent protein) for cellular localization studies

• Key Structural Features: Intact 32-amino-acid structure essential for biological activity; proteolytic cleavage or fragmentation ablates membranolytic function

• Known Synonyms: Anticancer peptide PNC-27, HDM-2-binding anticancer peptide, Membrane-active p53-HDM2 blocking peptide

• Supplier Identification: PubChem CID available; multiple commercial suppliers (Oxford Peptides, BOC Sciences, MedChemExpress, AbMole BioScience)

Database Links:

• PubChem: CID registration available (sequence-based)

• UniProt: Not applicable; synthetic engineered peptide

• PDB: p53(12-26) domain coordinates available as PDB entry 1YCR

• NCBI: Extensive literature database on anticancer peptides and cancer cell death

Important Note: PNC-27 differs critically from p53 peptide agonists by its C-terminal membrane-penetrating domain and its capacity to bind membrane-localized HDM-2 rather than nuclear HDM-2.

PNC-27 – Research

PNC-27 is an investigational synthetic anticancer peptide designed to selectively kill cancer cells by targeting HDM-2 (also known as MDM2), a protein overexpressed on the plasma membranes of tumor cells but minimally present on normal cells. Structurally, it fuses the HDM-2-binding domain from p53 residues 12-26 (Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu) to a membrane residency/penetrating peptide (Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly) on its C-terminus. This chimeric design enables PNC-27 to bind membrane HDM-2, adopt a membrane-active alpha-helical conformation, and form transmembrane pores, leading to rapid necrosis (not apoptosis) via extrusion of cellular contents. Critically, this mechanism is p53-independent, making it effective against p53-mutant or null cancers. Research spans in vitro cell lines (solid and hematologic tumors), ex vivo primary human cancers, and in vivo mouse models, showing tumor-specific cytotoxicity without harming normal cells. No human clinical trials are reported as of 2025; all data remain preclinical. Key implications: potential broad-spectrum therapy bypassing chemotherapy resistance, especially for HDM-2-overexpressing tumors like pancreatic, breast, leukemia, and ovarian cancers.

Study: Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
Benefits: Induces selective membranolysis in cancer cells (100% killing in 90 min at high doses), spares untransformed cells, eradicates tumors in nude mice, HDM-2 membrane expression as tumor biomarker
Link: https://www.pnas.org/doi/10.1073/pnas.0909364107
Summary: In this foundational PNAS study, researchers confirmed PNC-27's 3D structure superimposes on p53(17-26)-HDM-2 crystal (rms deviation 1.7-2.5 Å), enabling native binding. Western blots showed HDM-2 enriched 4-9 fold in membranes of cancer lines (MIA-PaCa-2 pancreatic, MCF-7 breast, A-2058 melanoma) vs. untransformed controls (MCF-10-2A, AG13145 fibroblasts). Confocal microscopy revealed colocalization (yellow fluorescence) of fluorescent PNC-27 with HDM-2 in cancer membranes within minutes, absent in normal cells. Co-IP confirmed specific binding (blocked by excess unlabeled PNC-27/28, not PNC-29 control). Transfecting membrane-targeted HDM-2 (HDM-2-CVVK) into MCF-10-2A rendered them susceptible: LDH release doubled, viability dropped 3-fold vs. controls (p<0.01), without apoptosis (no caspase rise). PNC-27 remained intact (double-fluorophore intact) during lysis. In vivo, prior work showed tumor regression in mice. Mechanistic insight: HDM-2 anchors PNC-27 in cancer membranes for pore formation; normal cells lack this, allowing peptide degradation/entry without lysis. This selectivity exploits cancer-specific HDM-2 translocation, offering a novel membranolytic paradigm vs. traditional apoptosis inducers.

Study: Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in Leukemia Cells But Not in Normal Hematopoietic Cells
Benefits: Kills AML lines (U937, OCI-AML3, HL-60) via 100% necrosis/LDH release in 4 hours, spares murine leukocytes/lymphocytes, potential for hematologic malignancies
Link: https://pubmed.ncbi.nlm.nih.gov/32878773/
Summary: Flow cytometry confirmed high HDM-2 membrane expression on three AML lines: U937 (monocytic), OCI-AML3 (myelomonocytic), HL-60 (promyelocytic). PNC-27 (dose-dependent, 50-200 μg/ml) bound membrane HDM-2, triggering necrosis (MTT viability <10%, LDH release >80% in 4h) without annexin V/caspase-3 apoptosis. Normal hematopoietic controls showed no HDM-2 membrane signal, no cytotoxicity (LDH <10%). Colocalization microscopy showed PNC-27-HDM-2 overlap in leukemia membranes. Mechanism: pore formation extrudes contents selectively. Why significant? AML often resists apoptosis-based therapies; PNC-27's necrosis bypasses this, targeting primitive/stem-like cells (HL-60/K562 models). Ex vivo expansion suggests bedside translation potential for refractory leukemia, where HDM-2 membranosis correlates with poor prognosis.

Study: The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells
Benefits: 100% necrosis in p53-null K562 leukemia (stem-like) via LDH release, HDM-2 membranosis in early/non-solid tumors, p53-independent
Link: https://pubmed.ncbi.nlm.nih.gov/25117093/
Summary: K562 (p53-homozygously deleted, stem/primitive leukemia) expressed abundant membrane HDM-2 (confirmed microscopy/Western). PNC-27 colocalized with HDM-2, inducing near-100% killing (LDH release) vs. no effect on murine leukocytes. Caspase-3/7 negative (necrosis confirmed). Controls (PNC-29) inert. Extends prior solid tumor work to non-solid/hematologic, proving mechanism holds for stem-like cells lacking p53. Tumor specificity: normal cells degrade PNC-27; cancer HDM-2 stabilizes it for lysis. Clinical angle: targets therapy-resistant, p53-mutant clones driving relapse.

Study: Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption
Benefits: Dual action—plasma membrane pores + mitochondrial disruption (mitotracker loss), blocks fibrosis/invasion, enhanced necrosis in pancreatic cancer
Link: https://pubmed.ncbi.nlm.nih.gov/38802154/
Summary: In MIA-PaCa-2 pancreatic cells, anti-HDM-2(p53-site) mAb blocked PNC-27 necrosis (LDH drop 80%), proving binding specificity (residues 1-109). PNC-27 entered cells, disrupting mitochondria (mitotracker efflux, no lysotracker effect) but not lysosomes. Immuno-EM showed gold-labeled PNC-27 on mitochondrial membranes. Dual hit: plasma pores initiate necrosis; mitochondrial binding amplifies via energy collapse/ROS. Pancreatic relevance: HDM-2 drives invasion; PNC-27 counters without p53 reliance. 2024 update refines "poptosis" (peptide-pore-osis) model.

PNC-27 – Research Links